Primary adenocarcinoma of the urinary bladder: Value of cell cycle biomarkers

American Journal of Clinical Pathology

Volumn 135, Issue 6, 2011, Pages 822-830

  Kapur, Payal ^a   Lotan, Yair ^a   King, Ellen ^a   Kabbani, Wareef ^a   Mitra, Anirban P ^b   Mosbah, Ahmed ^c   Abol Enein, Hassan ^c   Ghoneim, Mohamed ^c   Youssef, Ramy F ^a,c  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c MANSOURA UNIVERSITY   (Egypt)

Author keywords

Adenocarcinoma of the urinary bladder; Bladder cancer markers; Immunohistochemistry

Indexed keywords

BIOLOGICAL MARKER; CYCLIN E; KI 67 ANTIGEN; PROTEIN P21; PROTEIN P27; PROTEIN P53;

ADULT; AGED; ARTICLE; BLADDER CARCINOMA; CANCER GRADING; CANCER MORTALITY; CANCER RECURRENCE; CANCER STAGING; CELL CYCLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MALE; PRIORITY JOURNAL; PROGNOSIS; SCHISTOSOMIASIS; TISSUE MICROARRAY;

ADENOCARCINOMA; ADULT; AGED; COHORT STUDIES; CYCLIN E; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYSTECTOMY; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; KI-67 ANTIGEN; LYMPH NODES; MALE; MICROARRAY ANALYSIS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROLIFERATING CELL NUCLEAR ANTIGEN; STAINING AND LABELING; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53; URINARY BLADDER NEOPLASMS;

EID: 79957769617     PISSN: 00029173     EISSN: 19437722     Source Type: Journal    
DOI: 10.1309/AJCP76KUVOTBKQRY     Document Type: Article

References (30)

1. Abol-Enein H, Kava BR, Carmack AJ. Nonurothelial cancer of the bladder. Urology. 2007;69:93-104.
2. el-Mekresh MM, el-Baz MA, Abol-Enein H, et al. Primary adenocarcinoma of the urinary bladder: a report of 185 cases. Br J Urol. 1998;82:206-212.
3. Zaghloul MS, Nouh A, Nazmy M, et al. Long-term results of primary adenocarcinoma of the urinary bladder: a report on 192 patients. Urol Oncol. 2006;24:13-20. (Pubitemid 43097350)
4. Kantor AF, Hartge P, Hoover RN, et al. Epidemiological characteristics of squamous cell carcinoma and adenocarcinoma of the bladder. Cancer Res. 1988;48:3853-3855.
5. Dahm P, Gschwend JE. Malignant non-urothelial neoplasms of the urinary bladder: a review. Eur Urol. 2003;44:672-681. (Pubitemid 37542925)
6. Rogers CG, Palapattu GS, Shariat SF, et al. Clinical outcomes following radical cystectomy for primary nontransitional cell carcinoma of the bladder compared to transitional cell carcinoma of the bladder. J Urol. 2006;175:2048-2053. (Pubitemid 43668580)
7. Shariat SF, Zlotta AR, Ashfaq R, et al. Cooperative effect of cell-cycle regulators expression on bladder cancer development and biologic aggressiveness. Mod Pathol. 2007;20:445-459. (Pubitemid 46482368)
8. Shariat SF, Ashfaq R, Sagalowsky AI, et al. Predictive value of cell cycle biomarkers in nonmuscle invasive bladder transitional cell carcinoma. J Urol. 2007;177:481-487. (Pubitemid 46054033)
9. Shariat SF, Ashfaq R, Sagalowsky AI, et al. Association of cyclin D1 and E1 expression with disease progression and biomarkers in patients with nonmuscle-invasive urothelial cell carcinoma of the bladder. Urol Oncol. 2007;25:468-475. (Pubitemid 350151896)
10. Shariat SF, Ashfaq R, Sagalowsky AI, et al. Correlation of cyclin D1 and E1 expression with bladder cancer presence, invasion, progression, and metastasis. Hum Pathol. 2006;37:1568-1576. (Pubitemid 44792223)
11. Margulis V, Shariat SF, Ashfaq R, et al. Ki-67 is an independent predictor of bladder cancer outcome in patients treated with radical cystectomy for organ-confined disease. Clin Cancer Res. 2006;12:7369-7373. (Pubitemid 46095410)
12. Shariat SF, Bolenz C, Godoy G, et al. Predictive value of combined immunohistochemical markers in patients with pT1 urothelial carcinoma at radical cystectomy. J Urol. 2009;182:78-84.
13. Shariat SF, Chade DC, Karakiewicz PI, et al. Combination of multiple molecular markers can improve prognostication in patients with locally advanced and lymph node positive bladder cancer. J Urol. 2010;183:68-75.
14. Shariat SF, Lotan Y, Karakiewicz PI, et al. p53 predictive value for pT1-2 N0 disease at radical cystectomy. J Urol. 2009;182:907-913.
15. Shariat SF, Bolenz C, Karakiewicz PI, et al. p53 expression in patients with advanced urothelial cancer of the urinary bladder. BJU Int. 2010;105:489-495.
16. Shariat SF, Karakiewicz PI, Ashfaq R, et al. Multiple biomarkers improve prediction of bladder cancer recurrence and mortality in patients undergoing cystectomy. Cancer. 2008;112:315-325.
17. Shariat SF, Tokunaga H, Zhou J, et al. p53, p21, pRB, and p16 expression predict clinical outcome in cystectomy with bladder cancer. J Clin Oncol. 2004;22:1014-1024. (Pubitemid 41095033)
18. Shariat SF, Kim J, Raptidis G, et al. Association of p53 and p21 expression with clinical outcome in patients with carcinoma in situ of the urinary bladder. Urology. 2003;61:1140-1145. (Pubitemid 36693989)
19. Shaaban AA, Elbaz MA, Tribukait B. Primary nonurachal adenocarcinoma in the bilharzial urinary bladder: deoxyribonucleic acid flow cytometric and morphologic characterization in 93 cases. Urology. 1998;51:469-476. (Pubitemid 28136688)
20. Rosen DG, Huang X, Deavers MT, et al. Validation of tissue microarray technology in ovarian carcinoma. Mod Pathol. 2004;17:790-797. (Pubitemid 38843361)
21. Sun W, Zhang PL, Herrera GA. p53 protein and Ki-67 overexpression in urothelial dysplasia of bladder. Appl Immunohistochem Mol Morphol. 2002;10:327-331. (Pubitemid 35453691)
22. Esrig D, Spruck CH III, Nichols PW, et al. p53 nuclear protein accumulation correlates with mutations in the p53 gene, tumor grade, and stage in bladder cancer. Am J Pathol. 1993;143:1389-1397.
23. Ioachim E, Michael M, Stavropoulos NE, et al. Expression patterns of cyclins D1, E and cyclin-dependent kinase inhibitors p21(Waf1/Cip1) and p27(Kip1) in urothelial carcinoma: correlation with other cell-cycle-related proteins (Rb, p53, Ki-67 and PCNA) and clinicopathological features. Urol Int. 2004;73:65-73. (Pubitemid 38969895)
24. Pfister C, Moore L, Allard P, et al. Predictive value of cell cycle markers p53, MDM2, p21, and Ki-67 in superficial bladder tumor recurrence. Clin Cancer Res. 1999;5:4079-4084. (Pubitemid 30013788)
25. Vogelstein B, Lane D, Levine AJ. Surfing the p53 network. Nature. 2000;408:307-310.
26. Bolenz C, Lotan Y. Molecular biomarkers for urothelial carcinoma of the bladder: challenges in clinical use. Nat Clin Pract Urol. 2008;5:676-685.
27. Badr KM, Nolen JD, Derose PB, et al. Muscle invasive schistosomal squamous cell carcinoma of the urinary bladder: frequency and prognostic significance of p53, BCL-2, HER2/neu, and proliferation (MIB-1). Hum Pathol. 2004;35:184-189. (Pubitemid 38240900)
28. Haitel A, Posch B, El-Baz M, et al. Bilharzial related, organ confined, muscle invasive bladder cancer: prognostic value of apoptosis markers, proliferation markers, p53, E-cadherin, epidermal growth factor receptor and c-erbB-2. J Urol. 2001;165:1481-1487. (Pubitemid 32410219)
29. Grignon DJ, Ro JY, Ayala AG, et al. Primary adenocarcinoma of the urinary bladder: a clinicopathologic analysis of 72 cases. Cancer. 1991;67:2165-2172.
30. Anderström C, Johansson SL, von Schultz L. Primary adenocarcinoma of the urinary bladder: a clinicopathologic and prognostic study. Cancer. 1983;52:1273-1280. (Pubitemid 13006466)